The glypican family

Extracellular Matrix: Pathobiology and Signaling

Volumn , Issue , 2012, Pages 209-220

  Filmus, Jorge ^a,b   Capurro, Mariana ^a,b  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897430059     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Ai, X., Do, A. T., Lozynska, O., Kusche-Gullberg, M., Lindhal, U., and Emerson, C. P. (2003). QSulf1 remodels the 6-O sulfation states of cell surface proteoglycans to promote Wnt signaling. J Cell Biol 162, 341-351.
2. Aikawa, T., Whipple, C. A., Lopez, M. E., et al. (2008). Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest 118, 89-99.
3. Akiyama, T., Kamimura, K., Firkus, C., Takeo, S., Shimmi, O., and Nakato, H. (2008). Dally regulates Dpp morphogen gradient formation by stabilizing Dpp on the cell surface. Dev Biol 313, 408-419.
4. Ayers, K. L., Gallet, A., Staccini-Lavenant, L., and Therond, P. P. (2010). The long-range activity of hedgehog is regulated in the apical extracellular space by the glypican Dally and the hydrolase Notum. Dev Cell 18, 605-620.
5. Belenkaya, T. Y., Han, C., Yan, D., et al. (2004). Drosophila Dpp morphogen movement is independent of dynamin-mediated endocytosis but regulated by the glypican members of heparan sulfate proteoglycans. Cell 119, 231-244.
6. Bishop, J. R., Schuksz, M., and Esko, J. D. (2007). Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1036.
7. Bruix, J., and Sherman, M. (2011). Management of hepatocellular carcinoma: an update. Hepatology 53, 1020-1022.
8. Campos-Xavier, A. B., Martinet, D., Bateman, J., et al. (2009). Mutations in the heparan-sulfate proteoglycan glypican-6 (GPC6) impair endochodral ossification and cause recessive omodysplasia. Am J Hum Genet 84, 760-770.
9. Cano-Gauci, D. F., Song, H. H., Yang, H., et al. (1999). Glypican-3-deficient mice exhibit the overgrowth and renal abnormalities typical of the Simpson-Golabi-Behmel syndrome. J Cell Biol 146, 255-264.
10. Capurro, M., Wanless, I. R., Sherman, M., et al. (2003). Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125, 81-90.
11. Capurro, M., Xiang, Y. Y., Lobe, C., and Filmus, J. (2005a). Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65, 6245-6254.
12. Capurro, M. I., Li, F., and Filmus, J. (2009). Overgrowth of a mouse model of Simpson-Golabi-Behmel syndrome is partly mediated by Indian Hedgehog. EMBO Rep 10, 901-907.
13. Capurro, M. I., Shi, W., Sandal, S., and Filmus, J. (2005b). Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma. J Biol Chem 280, 41201-41206.
14. Capurro, M. I., Xu, P., Shi, W., Li, F., Jia, A., and Filmus, J. (2008). Glypican-3 inhibits hedgehog signaling during development by competing with Patched for Hedgehog binding. Dev Cell 14, 700-711.
15. Capurro, M. I., Shi, W., and Filmus, J. (2012). J.Cell Sci., in press.
16. DeBaun, M. R., Ess, J., and Saunders, S. (2001). Simpson Golabi Behmel syndrome: progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition. Mol Genet Metab 72, 279-286.
17. De Cat, B., Muyldermans, S. Y., Coomans, C., et al. (2003). Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol 163, 625-635.
18. Dejima, K., Kanai, M. I., Akiyama, T., Levings, D. C., and Nakato, H. (2011). Novel contactdependent bone morphogenetic protein (BMP) signaling mediated by heparan sulfate proteoglycans. J Biol Chem 286, 17103-17111.
19. Desbordes, S. C., and Sanson, B. (2003). The glypican Dally-like is required for hedgehog signalling in the embryonic epidermis of Drosophila. Development 130, 6245-6255.
20. Di Tommaso, L., Destro, A., Seok, J. Y., et al. (2009). The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 50, 746-754.
21. Eugster, C., Panakova, D., Mahmoud, A., and Eaton, S. (2007). Lipoprotein-heparan sulfate interactions in the Hh pathway. Dev Cell 13, 57-71.
22. Feng, M., Kim, H., and Ho, M. (2011). Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer 128, 2246-2247.
23. Filmus, J., Capurro, M., and Rast, J. (2008). Glypicans. Genome Biol 9, 224.
24. Franch-Marro, X., Marchand, O., Piddini, E., Ricardo, S., Alexandre, C., and Vincent, J. P. (2005). Glypicans shunt the wingless signal between local signalling and further transport. Development 132, 659-666.
25. Fujise, M., Takeo, S., Kamimura, K., et al. (2003). Dally regulates Dpp morphogen gradient formation in the Drosophila wing. Development 130, 1515-1522.
26. Gallet, A., Staccini-Lavenant, L., and Therond, P. P. (2008). Cellular trafficking of the glypian Dally-like is required for full-strength hedgehog signaling and wingless transcytosis. Dev Cell 14, 712-725.
27. Guo, Z., and Wang, Z. (2009). The glypican Dally is required in the niche for the maintenance of germline stem cells and short-range BMP signaling in the Drosophila ovary. Development 136, 3627-3635.
28. Gutierrez, J., and Brandan, E. (2010). A novel mechanism of sequestering FGF-2 by glypican in lipid rafts, allowing skeletal muscle differentiation. Mol Cell Biol 30, 1634-1649.
29. Hartwig, S., Hu, M. C., Cella, C., Piscione, T., Filmus, J., and Rosenblum, N. D. (2005). Glyican-3 modulates inhibitory Bmp2-Smad signaling to control renal development in vivo. Mech Dev 122, 928-938.
30. Hayashi, Y., Kobayashi, S., and Nakato, H. (2009). Drosophila glypicans regulate the germline stem cell niche. J Cell Biol 187, 473-480.
31. Hippo, Y., Watanabe, K., Watanabe, A., et al. (2004). Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 64, 2418-2423.
32. Ho, M., and Kim, H. (2010). Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 47, 333-338.
33. Hsu, H. C., Cheng, W., and Lai, P. L. (1997). Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temorospatial distribution. Cancer Res 57, 5179-5184.
34. Ishiguro, T., Sugimoto, M., Kinoshita, Y., et al. (2008). Anti-glypican-3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 68, 9832-9838.
35. Jackson, S. M., Nakato, H., Sugiura, M., et al. (1997). Dally, a Drosophila glypican, controls celular responses to the TGF-beta-related morphogen Dpp. Development 124, 4113-4120.
36. Jen, Y. H. L., Musacchio, M., and Lander, A. D. (2009). Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis. Neural Dev 4, 33.
37. Johnson, K. G., Tenney, A. P., Ghose, A., et al. (2006). The HSPGs syndecan and Dallylike bind the receptor phophatase LAR and exert distinct effects on synaptic development. Neuron 49, 517-531.
38. Kim, M. S., Saunders, A. M., Hamaoka, B., et al. (2011). Structure of the protein core of the glypican Dally-like and localization of a region important for hedgehog signaling. Porc. Natl. Acad. Sci. U.S.A. 108, 13112-13117.
39. Kleeff, J., Ishiwata, T., Kumbasar, A., et al. (1998). The cell surface heparan sulfate proteoglycan glypican-1 regulates growth factor in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 102, 1662-1673.
40. Komori, H., Nakatsura, T., Senju, S., et al. (2006). Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12, 2689-2697.
41. Kreuger, J., Perez, L., Giraldez, A. J., and Cohen, S. M. (2004). Opposing activities of Dally-like glypican at high and low levels of Wingless morphogen activity. Dev Cell 7, 503-512.
42. Li, F., Shi, W., Capurro, M., and Filmus, J. (2011). Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol 192, 691-704.
43. Libbrecht, L., Severi, T., Cassiman, D., et al. (2006). Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 30, 1405-1411.
44. Lin, X., and Perrimon, N. (1999). Dally cooperates with Drosophila Frizzled 2 to transduce Wingless signaling. Nature 400, 281-284.
45. Lum, L., Yao, S., Mozer, B., et al. (2003). Identification of hedgehog pathway components by RNAi in Drosophila cultured cells. Science 299, 2039-2045.
46. Luo, J. H., Ren, B., Keryanov, S., et al. (2006). Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 44, 1012-1024.
47. Nakatsura, T., Yoshitake, Y., Senju, S., et al. (2003). Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306, 16-25.
48. Neri, G., Gurrieri, F., Zanni, G., and Lin, A. (1998). Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 79, 279-283.
49. Ng, A., Wong, M., Viviano, B., et al. (2009). Loss of glypican-3 function causes growth factor-dependent defects in cardiac and coronary vascular development. Dev Biol 335, 208-215.
50. Ohkawara, B., Yamamoto, T. S., Tada, M., and Ueno, N. (2003). Role of glypican 4 in the regulation of convergent extension movements during gastrulation in Xenopus laevis. Development 130, 2129-2138.
51. Okamoto, K., Tokunaga, K., Doi, K., et al. (2011). Common variation in GPC5 is associated with acquired nephrotic syndrome. Nat Genet 43, 459-463.
52. Paine-Saunders, S., Viviano, B. L., Zupicich, J., Skarnes, W. C., and Saunders, S. (2000). Gly-pican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol 225, 179-187.
53. Patil, M. A., Chua, M. S., Pan, K. H., et al. (2005). An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 24, 3737-3747.
54. Pilia, G., Hughes-Benzie, R. M., MacKenzie, A., et al. (1996). Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 12, 241-247.
55. Rawson, J. M., Dimitroff, B., Johnson, K. G., et al. (2005). The heparan sulfate proteoglycans Dally-like and Syndecan have distinct functions in axon guidance and visual-system assembly in Drosophila. Curr Biol 15, 833-838.
56. Saunders, S., Paine-Saunders, S., and Lander, A. D. (1997). Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain. Dev Biol 190, 78-93.
57. Shao, M., Liu, Z. Z., Wang, C. D., et al. (2009). Down syndrome critical region protein 5 regulates membrane localization of Wnt receptors, Dishevelled stability and convergent eeextension in vertebrate embryos. Development 136, 2121-2131.
58. Shiba, K., Hu, N., and Bronner-Fraser, M. (2010). Altering glypican-1 levels modulates canonical Wnt signaling during trigeminal placode development. Dev Biol 348, 107-118.
59. Smart, A. D., Course, M. M., Rawson, J., Selleck, S. B., Van Vactor, D., and Johnson, K. G. (2011). Heparan sulfate proteoglycan specificity during axon pathway formation in Drosophila embryo. Dev Neurobiol 71, 608-618.
60. Song, H. H., and Filmus, J. (2002). The role of glypicans in mammalian development. Biochim Biophys Acta 1573, 241-246.
61. Song, H. H., Shi, W., Xiang, Y., and Filmus, J. (2005). The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 280, 2116-2125.
62. Su, G., Meyer, K., Nandini, C. D., Qiao, D., Salamat, S., and Friedl, A. (2006). Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am J Pathol 168, 2014-2026.
63. Svensson, G., Awad, W., Hakansson, M., Mani, K., and Logan, D. T. (2012). Crystal structure of N-glycosylated human glypican-1 core protein. J Biol Chem 287, 14040-14051.
64. Taylor, D. R., Whitehouse, I. J., and Hooper, N. M. (2009). Glypican-1 mediates both prion protein lipid raft association and disease isoform formation. PLOS Pathog 5, e1000666.
65. Topczewsky, J., Sepich, D. S., Myers, D. C., et al. (2001). The zebrafish glypican knypek controls cell polarity during gastrulation movements of convergent extension. Dev Cell 1, 251-264.
66. Tsuda, M., Kamimura, K., Nakato, H., et al. (1999). The cell-surface proteoglycan Dally regulates Wingless signaling in Drosophila. Nature 400, 276-280.
67. Vyas, N., Goswami, D., Manonmani, A., et al. (2008). Nanoscale organization of hedgehog is essential for long-range signaling. Cell 133, 1214-1227.
68. Watanabe, K., Yamada, H., and Yamaguchi, Y. (1995). K-glypican: a novel GPI-linked heparan sulfate proteoglycan that is highly expressed in developing brain and kidney. J Cell Biol 130, 1207-1218.
69. Williams, E. H., Pappano, W. N., Saunders, A. M., Kim, M. S., Leahy, D. J., and Beachy, P. A. (2010). Dally-like core protein and its mammalian homologues mediate stimulatory and inhibitory effects on Hedgehog signal response. Proc Natl Acad Sci U S A 107, 5869-5874.
70. Williamson, D., Selfe, J., Gordon, T., et al. (2007). Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res 67, 57-65.
71. Yan, D., and Lin, X. (2007). Drosophila glypican Dally-like acts in FGF-receiving cells to modulate FGF signaling during tracheal morphogenesis. Dev Biol 312 (1), 203-216.
72. Yan, D., Wu, Y., Feng, Y., Lin, S. C., and Lin, X. (2009). The core protein of glypican Dally-like determines its biphasic activity in wingless morphogen signaling. Dev Cell 17, 470-481.
73. Yan, D., Wu, Y., Yang, Y., Belenkaya, T. Y., Tang, X., and Lin, X. (2010). The cell-surface proteins Dally-like and Ihog differentially regulate Hedgehog signaling strength and range during development. Development 137, 2033-2044.
74. Zhang, F., Ronca, F., Linhardt, R. J., and Margolis, R. U. (2004). Structural determinants of heparan sulfate interactions with Slit proteins. Biochem Biophys Res Commun 317, 352-357.
75. Zhu, A. X., Gold, P. J., El-Khoueiry, A. B., Abrams, T. A., Morikawa, H., and Philip, P. A. (2011). A phase 1 study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. J Clin Oncol 29 (Suppl., abstr. 4085).
76. Zittermann, S. I., Capurro, M. I., and Filmus, J. (2010). Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 126, 1291-1301.